Contamination of pharmaceutical products by the Burkholderia cepacia complex and its possible impacts on healthcare and industry: A bibliographic review
DOI:
https://doi.org/10.33448/rsd-v13i2.45032Keywords:
B. cepacia; Medicines; Cosmetics; Contamination; Health surveillance of products.Abstract
The Burkholderia cepacia complex (BcC) is a group of bacteria of the genus Burkholderia known to cause opportunistic infections, being able to acquire resistance to antibiotics and antiseptics. Despite this, it is a group of bacteria that is disguised in the pharmaceutical environment and its potential risk as a contaminating agent is still disregarded, since the Brazilian pharmacopeial methods that establish the microbiological limits for pharmaceutical products do not include them. Therefore, the objective of this article was to carry out a bibliographic review on cases of contamination of pharmaceutical products (of common and hospital use) by the BcC around the world and discuss the possible health and economic impacts based on data obtained through searches in PubMed, VHL, Scielo and Scopus databases. Thus, it is suggested that for the circulation of these drugs it is necessary to update pharmacopeial methods (mainly for analysis of water and finished product) including the BcC complex.
References
Abbott I. J. & Anton Y. P. (2015). Stenotrophomonas, Achromobacter, and nonmelioid Burkholderia species: antimicrobial resistance and therapeutic strategies. Seminars in respiratory and critical care medicine, 36(01). Thieme Medical Publishers. 10.1055/s-0034-1396929
Abdallah M., Abdallah H. A., & Memish, Z. A. (2018). Burkholderia cepacia complex outbreaks among non-cystic fibrosis patients in the intensive care units: a review of adult and pediatric literature. Infez Med, 26(4), 299-307.
Abdelfattah R., Al-Jumaah S., Al-Qahtani A., Al-Thawadi S., Barron I., & Al-Mofada S. (2018). Outbreak of Burkholderia cepacia bacteraemia in a tertiary care centre due to contaminated ultrasound probe gel. Journal of Hospital Infection, 98(3), 289-294.
ABIHPEC. (2022). Panorama global de consumo de produtos de Higiene Pessoal, Perfumaria e Cosméticos marcam o primeiro dia da Semana ABIHPEC de Mercado 2022. Associação Brasileira das Indústrias de Higiene Pessoal, Perfumaria e Cosméticos (ABIHPEC). https://abihpec.org.br/comunicado/panorama-global-de-consumo-de-produtos-de-higiene-pessoal-perfumaria-e-cosmeticos-marcam-o-primeiro-dia-da-semana-abihpec-de-mercado-2022/
Ahn Y., Kim J. M., Kweon O., Kim S. J., Jones R. C., Woodling K., da Costa G. G., LiPuma J. J., Hussong D., Marasa B. S., & Cerniglia C. E. (2016). Intrinsic resistance of Burkholderia cepacia complex to benzalkonium chloride. MBio, 7(6), e01716-16.
Ángeles-Garay U., Zacate-Palacios Y., López-Herrera J. R., Hernández-Sánchez E. A., Silva-Sánchez J., de Jesús Ascencio-Montiel I. (2012). Infecciones urinarias nosocomiales Contaminación de gel con Burkholderia cepacia. Revista Médica del Instituto Mexicano del Seguro Social, 50(6), 615-622.
ANVISA. (2019). Resolução da Diretoria Colegiada - RDC Nº 301, De 21 de agosto de 2019. Agência Nacional de Vigilância Sanitária ANVISA. Portal ANVISA. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-301-de-21-de-agosto-de-2019-211914064
ANVISA. (2013). Resolução da Diretoria Colegiada - RDC Nº 48, De 25 de outubro de 2013. Agência Nacional de Vigilância Sanitária ANVISA. Portal ANVISA. https://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2013/rdc0048_25_ 10_20 13.html
ANVISA. (1999). Resolução da Diretoria Colegiada - RDC Nº 481, De 23 de setembro de 1999. Agência Nacional de Vigilância Sanitária ANVISA. Portal ANVISA. https://files.cercomp.ufg.br/weby/up/130/o/RDC_481_de_1999.pdf
ANVISA. (2022). Resolução da Diretoria Colegiada - RDC Nº 658, De 30 de março de 2022. Agência Nacional de Vigilância Sanitária ANVISA. Portal ANVISA. http://antigo.anvisa.gov.br/documents/10181/6415119/RDC_658_2022_.pdf/aff5 cdd7-4ad1-40e8-8751-87df566e6424.
ASTM. (2019). Standard Test Method for Preservatives in Water-Containing Cosmetics. American Society for Testing and Materials (ASTM). E640-06.
Becker S. L., Berger F. K., Feldner S. K., Karliova I., Haber M., Mellmann A., Hans-Joachim S., & Gärtner B. (2018). Outbreak of Burkholderia cepacia complex infections associated with contaminated octenidine mouthwash solution, Germany, August to September 2018. Eurosurveillance, 23(42), 1800540.
Botelho, L. L. R., Cunha, C. A., & Macedo, M. (2011). O método da revisão integrativa nos estudos organizacionais. Gestão e Sociedade, 5(11), 121-136.
Burkholder, W. H. (1950). Sour skin, a bacterial rot of onion bulbs. Phytopathology, v. 40, p. 115-17
Coenye T. & Vandamme P. (2003). Diversity and significance of Burkholderia species occupying diverse ecological niches. Environmental microbiology, 5(9), 719-729.
Coenye T., Vandamme P., Govan J. R., & LiPuma J. J. (2001). Taxonomy and identification of the Burkholderia cepacia complex. Journal of clinical microbiology, 39(10), 3427-3436.
CTFA. (2007). Quality Assurance Guidelines. The Personal Care Products Council, Washington, DC. Cosmetic, Toiletry and Fragrance Association (CFTA).
De Smet B., Veng C., Kruy L., Kham C., Van Griensven J., Peeters C., Ieng S., Phe T., Vlieghe E., & Jacobs J. (2013). Outbreak of Burkholderia cepacia bloodstream infections traced to the use of Ringer lactate solution as multiple-dose vial for catheter flushing, Phnom Penh, Cambodia. Clinical Microbiology and Infection, 19(9), 832-837.
De Volder A. L., Teves S., Isasmendi A., Pinheiro J. L., Ibarra L., Breglia N., Herrera T., Vazquez M., Hernandez C., & Degrossi J. (2021). Distribution of Burkholderia cepacia complex species isolated from industrial processes and contaminated products in Argentina. International Microbiology, 24(2), 157-167.
Dolan S., Dowell E., LiPuma J., Valdez S., Chan K., James J. (2011). An Outbreak of Burkholderia cepacia Complex Associated with Intrinsically Contaminated Nasal Spray. Infection Control & Hospital Epidemiology, 32(8), 804-810.
Du M., Song L., Wang Y., Suo J., Bai Y., Xing Y., Xie L., Liu B., Li L., Luo Y., & Yunxi L. (2021). Investigation and control of an outbreak of urinary tract infections caused by Burkholderia cepacian-contaminated anesthetic gel. Antimicrobial Resistance & Infection Control, 10(1), 1-7. https://doi.org/10.1186/s13756-020-00855-x
EMA. (2013). EMA publishes 2013 annual reports. European Medicines Agency (EMA).
FDA. (2021). FDA advises drug manufacturers that Burkholderia cepacia complex poses a contamination risk in non-sterile, water-based drug products. U.S. Food and Drug Administration. FDA. https://www.fda.gov/drugs/drug-safety-and-availability/fda-advises-drug-manufacturers-burkholderia-cepacia-complex- poses-contamination-risk-non-sterile
Glowicz J., Crist M., Gould C., Moulton-Meissner H., Noble-Wang J., de Man T. J., Perry K. A., Miller Z., Yang W. C., Langille S., Ross J., Garcia B., Kim J., Epson E., Black S., Pacilli M., LiPuma J. J., & Fagan R. (2018). A multistate investigation of health care–associated Burkholderia cepacia complex infections related to liquid docusate sodium contamination, January-October 2016. American journal of infection control, 46(6), 649-655. https://doi.org/10.1016/j.ajic.2017.11.018
Horsley A., Perry C., Martin K., Webb K., Turton J., Kenna D., & Jones A. (2011). Burkholderia latens infection in cystic fibrosis. Journal of Cystic Fibrosis, 10(4), 291-292. https://doi.org/10.1016/j.jcf.2011.01.001
Jacobson M., Wray R., Kovach D., Henry D., Speert D., & Matlow A. (2006). Sustained endemicity of Burkholderia cepacia complex in a pediatric institution, associated with contaminated ultrasound gel. Infection Control & Hospital Epidemiology, 27(4), 362-366. https://doi.org/10.1086/503343
Jimenez L. (2019). Analysis of FDA Enforcement Reports (2012-2019) to Determine the Microbial Diversity in Contaminated Non-Sterile and Sterile Drugs. American Pharmaceutical Review.
Ko S., An H. S., Bang J. H., & Park S. W. (2015). An outbreak of Burkholderia cepacia complex pseudobacteremia associated with intrinsically contaminated commercial 0.5% chlorhexidine solution. American Journal of Infection Control, 43(3), 266-268. https://doi.org/10.1016/j.ajic.2014.11.010
Kuzumoto K., Kubota N., Ishii K., Yumoto K., Ogiso Y., Nakamura T., Katsuyama T., Oana K., & Kawakami Y. (2011). Successful cessation of transmitting healthcare-associated infections due to Burkholderia cepacia complex in a neonatal intensive care unit in a Japanese children's hospital. European Journal of Medical Research, 16(12), 537-542. 10.1186/2047-783x-16-12-537
Lalitha P., Das M., Purva P. S., Karpagam R., Geetha M., Priya J. L., & Babu K. N. (2014). Postoperative endophthalmitis due to Burkholderia cepacia complex from contaminated anaesthetic eye drops. British Journal of Ophthalmology, 98(11), 1498-1502.
Lee S., Han S. W., Kim G., Lee J. C., & Kwon K. T. (2013). An outbreak of Burkholderia cenocepacia associated with contaminated chlorhexidine solutions prepared in the hospital. American Journal of Infection Control, 41(9), e93-e96.
Leong L. E., Lagana D., Carter G. P., Wang Q., Smith K., Stinear T. P., Shaw D., Sintchenko V., Wesselingh S. L., Bastian I., & Rogers G. B. (2018). Burkholderia lata infections from intrinsically con taminated chlorhexidine mouthwash, Australia, 2016. Emerging infectious diseases, 24(11), 2109. 10.3201/eid2411.171929
Marquez L., Jones K. N., Whaley E. M., Koy T. H., Revell P. A., Taylor R. S., Bernhardt M. B., Wagner J. L., Dunn J. J., LiPuma J. J., & Campbell J. R. (2017). An outbreak of Burkholderia cepacia complex infections associated with contaminated liquid docusate. infection control & hospital epidemiology, 38(5), 567-573. https://doi.org/10.1017/ice.2017.11
Martin M., Winterfeld I., Kramme E., Ewert I., Sedemund-Adib B., & Mattner F. (2012). Outbreak of Burkholderia cepacia complex caused by contaminated alcohol-free mouthwash. Der Anaesthesist, 61(1), 25-29.
Martinucci M., Roscetto E., Lula V. D., Votsi A., Catania M. R., & De Gregorio E. (2016). Accurate identification of members of the Burkholderia cepacia complex in cystic fibrosis sputum. Letters in Applied Microbiology, 62(3), 221-229. 10.1111/lam.12537
Mendes J. (2019). Mercado de cosméticos cresce, apesar da crise. Correio Brasiliense - Economia. https://www.correiobraziliense.com.br/app/noticia/economia
/2019/06/06/internas_economia,760579/mercado-de-cosmeticos-cresce-apesar-da-crise.shtml
Nannini E. C., Ponessa A., Muratori R., Marchiaro P., Ballerini V., Flynn L., & Limansky A. S. (2015). Polyclonal outbreak of bacteremia caused by Burkholderia cepacia complex and the presumptive role of ultrasound gel. Brazilian Journal of Infectious Diseases, 19, 543-545. 10.1016/j.bjid.2015.06.009
O Tempo, Jornal. (2014). Fora das Prateleiras - Anvisa suspende uso de sete lotes de antisséptico bucal. Portal O Tempo, 2014. https://www.otempo.com.br/brasil/anvisa-suspense-uso-de-sete-lotes-de-antisseptico-bucal-1.935778
Rhodes K. A. & Schweizer H. P. (2016). Antibiotic resistance in Burkholderia species. Drug Resistance Updates, 28, 82-90. 10.1016/j.drup.2016.07.003
Ribeiro W. (2019). Brasil é o 6° Mercado Farmacêutico do Mundo. ICTQ - Instituto de Ciência, Tecnologia e Qualidade, São Paulo, p. 1. https://ictq.com.br/industria-farmaceutica/1060-brasil-e-o-6-mercado-farmaceutico-do-mundo
Seelman S. L., Bazaco M. C., Wellman A., Hardy C., Fatica M. K., Huang M. C. J., Brown A. M., Garner K., Yang W. C., Norris C., Moulton-Meissner H., Paoline J., Kinsey C. B., Kim J. J., Kim M., Terashita D., Mehr J., Crosby A. J., Viazis S., & Crist M. B. (2022). Burkholderia cepacia complex outbreak linked to a no-rinse cleansing foam product, United States–2017–2018. Epidemiology & Infection, 150, e154.
SINDUSFARMA. (2022). Mercado farmacêutico deve crescer 12% este ano e 10% em 2023; empresas estão otimistas com emprego e crescimento da economia. Sindicato da Indústria Farmacêutica (SINDUSFARMA). https://sindusfarma.org.br/noticias /indice/exibir/17943-mercado-farmaceutico-deve-cresce
r-12-este-ano-e-10-em-2023-empresas-estao-otimistas-com-emprego-e-crescimento-da-economia
Singhal T., Shah S., & Naik R. (2015). Outbreak of Burkholderia cepacia complex bacteremia in a chemotherapy day care unit due to intrinsic contamination of an antiemetic drug. Indian journal of medical microbiology, 33(1), 117-119.
Song J. E., Kwak Y. G., Um T. H., Cho C. R., Kim S., Park I. S., Hwang J. H., Kim N. & Oh G. B. (2018). Outbreak of Burkholderia cepacia pseudobacteraemia caused by intrinsically contaminated commercial 0.5% chlorhexidine solution in neonatal intensive care units. Journal of Hospital Infection, 98(3), 295-299. 10.1016/j.jhin.2017.09.012
Srinivasan R., Santhakumari S., Poonguzhali P., Geetha M., Dyavaiah M., & Xiangmin L. (2021). Bacterial biofilm inhibition: A focused review on recent therapeutic strategies for combating the biofilm mediated infections. Frontiers in Microbiology, 12, 676458.
Sutton S. & Jimenez L. (2012). A Review of Reported Recalls Involving Microbiological Control 2004-2011 with Emphasis on FDA Considerations of" Objectionable Organisms". American Pharmaceutical Review, 15(1), 42.
Tavares M., Kozak M., Balola A., Coutinho C. P., Godinho C. P., Hassan A. A., Cooper V. S, & Sá-Correia I. (2020). Adaptation and survival of Burkholderia cepacia and B. contaminans during long-term incubation in saline solutions containing benzalkonium chloride. Frontiers in bioengineering and biotechnology, 8,630. doi: 10.3389/fbioe.2020.00630
Torbeck L., Raccasi D., Guilfoyle D. E, Friedman R. L, & Hussong D. (2011). Burkholderia cepacia: this decision is overdue. PDA Journal of Pharmaceutical Science and Technology, 65(5), 535-543. doi:10.5731/pdajpst.2011.00793
USP (2019). Microbiological Examination of Non-Sterile Products Tests for Burkholderia Cepacia Complex. United States Pharmacopeia. USP. In: PHARMACOPEIA, U. S. United States Pharmacopeia. Cap. 60.
Wiener-Well Y., Segonds C., Mazuz B., Kopuit P., & Assous M. V. (2014). Successful outbreak investigation of Burkholderia cepacia complex bacteremia in intensive care patients. American journal of infection control, 42(5), 580-581. 10.1016/j.ajic.2013.12.015
Wong J. K., Chambers L. C., Elsmo E. J., Jenkins T. L., Howerth E. W., Sánchez S., & Sakamoto K. (2018). Cellulitis caused by the Burkholderia cepacia complex associated with contaminated chlorhexidine 2% scrub in five domestic cats. Journal of veterinary diagnostic investigation, 30(5), 763-769. https://doi.org/10.1177/1040638718782
Wong S. C., Wong S. C, Chen J. H, Poon R. W, Hung D. L, Chiu K. H, Simon Y. C. S, Wing S. L., Tak M. C., Desmond Y. H. Y., Vivien W. M. C., Kwok-Yung Y., & Cheng V. C. (2020). Polyclonal Burkholderia cepacia complex outbreak in peritoneal dialysis patients caused by contaminated aqueous chlorhexidine. Emerging infectious diseases, 26(9), 1987-1997.
Yabuuchi E., Kosako Y., Oyaizu H., Yano I., Hotta H., Hashimoto Y., Ezaki T., & Arakawa M. (1992). Proposal of Burkholderia gen. nov. and transfer of seven species of the genus Pseudomonas homology group II to the new genus, with the type species Burkholderia cepacia (Palleroni and Holmes 1981) comb. nov. Microbiology and immunology, 36(12), 1251-1275.
Zou Q., Li N., Liu J., Li X., Wang Z., Ai X., Tao F., Qu M., Cai M., & Hu Y. (2020). Investigation of an outbreak of Burkholderia cepacia infection caused by drug contamination in a tertiary hospital in China. American Journal of Infection Control, 48(2), 199-203. 10.1016/j.ajic.2019.06.011
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Víctor Bitiano Bazani ; Ana Carolina Furian da Silva ; Kátia de Pádua Silva; Karina Cogo Müller
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
